CDK4 and breast cancer: Recently, US Food and Drug Administration (FDA) and European Medicine Agency (EMA) approved three orally highly selective inhibitors of CDK4/6 for HR-positive advanced or metastatic BC, namely palbociclib (PD0332991), ribociclib (LEE011), and abemaciclib (LY2835219).